home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Techniques May Help Antigens Be "Seen" By The Immune System

  December, 2 2000 11:09
your information resource in human molecular genetics
It's all in the presentation

Harnessing the body’s own immune system to fight cancers is elegantly simple in theory but has proven difficult in practice. Two new techniques may help bring researchers a step closer by overcoming one of the main teething problems—getting cancer-associated proteins (antigens) "seen" by the immune system (Nature Biotechnology, Vol. 18, Issue 12, 01 Dec 2000).

The major players here are the dendritic cells, which carry out the job of presenting the antigen to the immune system. This is an essential step in triggering an immune response against the foreign protein and thereby the cancer. However, dendritic cells have proven difficult to manipulate and coaxing them to adopt the cancer antigen can be tricky.

Andrew Mountain’s research team has got around this problem by delivering DNA encoding the cancer-associated antigen to dendritic cells. First, they mixed the DNA with a peptide that condenses it and encourages its uptake and exposed dendritic cells to the mixture. When the dendritic cells that had been modified were injected into mice, the researchers found an immune reaction that slows the growth of tumours.

Independently, Damir Vidovic and his colleagues have developed a way of encouraging antigen-presenting cells, including dendritic cells, to take up antigen directly. Because of similar, and therefore repulsive, charges, antigens do not naturally penetrate the cell membrane. Vidovic and his team have overcome this problem by linking two discrete peptides to the antigen. One peptide neutralizes the antigen’s charge, easing its passage across the membrane. The other frees the antigen inside the cell, allowing it to be more readily presented by the cell and evoking a strong immune response. The next stage will be to test whether these transformed cells can also halt tumour growth in mice.

Contact: (author)

Andy Mountain
Cobra Therapeutics
The Science Park
University of Keele
Keele, Staffordshire ST5 5SP
Email: andy.mountain@cobrat.com

Contact: (author)

Damir Vidovic
Dendreon Corporation
Seattle, WA 98121
Email: dvidovic@dendreon.com

(C) Nature Biotechnology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.